South Korea · Delayed Price · Currency is KRW L&K Biomed Statistics
Total Valuation
L&K Biomed has a market cap or net worth of KRW 112.43 billion. The enterprise value is 105.86 billion.
| Market Cap | 112.43B |
| Enterprise Value | 105.86B |
Important Dates
The last earnings date was Friday, May 29, 2026.
| Earnings Date | May 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
L&K Biomed has 22.35 million shares outstanding. The number of shares has decreased by -4.40% in one year.
| Current Share Class | 22.35M |
| Shares Outstanding | 22.35M |
| Shares Change (YoY) | -4.40% |
| Shares Change (QoQ) | +5.10% |
| Owned by Insiders (%) | 11.90% |
| Owned by Institutions (%) | 0.40% |
| Float | 19.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.84 |
| PB Ratio | 2.17 |
| P/TBV Ratio | 1.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.68 |
| EV / EBITDA | 31.52 |
| EV / EBIT | 180.80 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.64, with a Debt / Equity ratio of 0.53.
| Current Ratio | 1.64 |
| Quick Ratio | 0.89 |
| Debt / Equity | 0.53 |
| Debt / EBITDA | 7.73 |
| Debt / FCF | -1.72 |
| Interest Coverage | 0.26 |
Financial Efficiency
Return on equity (ROE) is -18.25% and return on invested capital (ROIC) is 1.51%.
| Return on Equity (ROE) | -18.25% |
| Return on Assets (ROA) | 0.50% |
| Return on Invested Capital (ROIC) | 1.51% |
| Return on Capital Employed (ROCE) | 1.35% |
| Weighted Average Cost of Capital (WACC) | 7.85% |
| Revenue Per Employee | 391.36M |
| Profits Per Employee | -72.91M |
| Employee Count | 101 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 0.20 |
Taxes
| Income Tax | -100.95M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.99% in the last 52 weeks. The beta is 0.61, so L&K Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -17.99% |
| 50-Day Moving Average | 6,793.80 |
| 200-Day Moving Average | 9,806.80 |
| Relative Strength Index (RSI) | 30.58 |
| Average Volume (20 Days) | 249,955 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, L&K Biomed had revenue of KRW 39.53 billion and -7.36 billion in losses. Loss per share was -353.17.
| Revenue | 39.53B |
| Gross Profit | 32.93B |
| Operating Income | 785.51M |
| Pretax Income | -8.23B |
| Net Income | -7.36B |
| EBITDA | 3.56B |
| EBIT | 785.51M |
| Loss Per Share | -353.17 |
Balance Sheet
The company has 26.58 billion in cash and 27.50 billion in debt, with a net cash position of -912.93 million or -40.85 per share.
| Cash & Cash Equivalents | 26.58B |
| Total Debt | 27.50B |
| Net Cash | -912.93M |
| Net Cash Per Share | -40.85 |
| Equity (Book Value) | 51.81B |
| Book Value Per Share | 2,662.47 |
| Working Capital | 33.96B |
Cash Flow
In the last 12 months, operating cash flow was -10.84 billion and capital expenditures -5.17 billion, giving a free cash flow of -16.01 billion.
| Operating Cash Flow | -10.84B |
| Capital Expenditures | -5.17B |
| Depreciation & Amortization | 2.77B |
| Net Borrowing | 27.20B |
| Free Cash Flow | -16.01B |
| FCF Per Share | -716.38 |
Margins
Gross margin is 83.30%, with operating and profit margins of 1.99% and -18.63%.
| Gross Margin | 83.30% |
| Operating Margin | 1.99% |
| Pretax Margin | -20.83% |
| Profit Margin | -18.63% |
| EBITDA Margin | 9.00% |
| EBIT Margin | 1.99% |
| FCF Margin | n/a |
Dividends & Yields
L&K Biomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.40% |
| Shareholder Yield | 4.40% |
| Earnings Yield | -6.55% |
| FCF Yield | -14.24% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
L&K Biomed has an Altman Z-Score of 2.26 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.26 |
| Piotroski F-Score | 3 |